Immatics (NASDAQ:IMTX) Sets New 52-Week Low - What's Next?

Immatics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Immatics shares hit a new 52-week low, falling to $5.87 intraday and last trading at $5.975, below the prior close of $6.10.
  • The company’s latest quarterly results missed expectations: it reported a loss of $0.58 per share versus a forecast loss of $0.51, while revenue of $7.84 million was below the $12.18 million consensus estimate.
  • Analyst views are mixed: five analysts rate the stock Buy and one rates it Sell, producing a “Moderate Buy” consensus and a $19 average price target. Separately, Perceptive Advisors increased its stake by buying 863,060 shares.
  • Five stocks we like better than Immatics.

Immatics N.V. (NASDAQ:IMTX - Get Free Report) shares hit a new 52-week low during mid-day trading on Thursday. The company traded as low as $5.87 and last traded at $5.9750, with a volume of 551,533 shares traded. The stock had previously closed at $6.10.

Wall Street Analysts Forecast Growth

Several research firms recently commented on IMTX. Weiss Ratings restated a "sell (d-)" rating on shares of Immatics in a research report on Friday, September 18th. Wall Street Zen cut Immatics from a "hold" rating to a "sell" rating in a research report on Saturday, October 31st. Mizuho set a $21.00 price objective on Immatics in a research note on Thursday, October 29th. Jefferies Financial Group reiterated a "buy" rating on shares of Immatics in a research note on Tuesday. Finally, Stifel Nicolaus assumed coverage on Immatics in a report on Tuesday, October 13th. They set a "buy" rating and a $15.00 price objective for the company. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Immatics has an average rating of "Moderate Buy" and a consensus target price of $19.00.

Check Out Our Latest Analysis on IMTX

Immatics Stock Down 2.5%

The stock's 50-day moving average price is $7.52 and its 200-day moving average price is $9.36. The company has a market capitalization of $812.90 million, a price-to-earnings ratio of -3.07 and a beta of 1.38.

Immatics (NASDAQ:IMTX - Get Free Report) last released its earnings results on Tuesday, November 10th. The company reported ($0.58) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.07). The firm had revenue of $7.84 million for the quarter, compared to the consensus estimate of $12.18 million. Immatics had a negative return on equity of 52.54% and a negative net margin of 533.26%. On average, equities research analysts anticipate that Immatics N.V. will post -2.03 EPS for the current year.

Insider Transactions at Immatics

In other Immatics news, Director Perceptive Advisors Llc bought 863,060 shares of the company's stock in a transaction on Wednesday, August 26th. The stock was bought at an average price of $8.69 per share, for a total transaction of $7,499,991.40. Following the transaction, the director owned 11,246,516 shares of the company's stock, valued at approximately $97,732,224.04. The trade was a 8.31% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 3.30% of the company's stock.

Institutional Trading of Immatics

Hedge funds have recently modified their holdings of the company. Goldman Sachs Group Inc. grew its holdings in shares of Immatics by 3.6% in the 3rd quarter. Goldman Sachs Group Inc. now owns 398,004 shares of the company's stock valued at $3,494,000 after buying an additional 13,833 shares during the period. Integral Health Asset Management LLC acquired a new position in Immatics in the third quarter valued at about $6,058,000. Marshall Wace LLP bought a new stake in shares of Immatics in the third quarter worth about $3,685,000. Aberdeen Group plc raised its position in shares of Immatics by 89.0% during the third quarter. Aberdeen Group plc now owns 1,235,460 shares of the company's stock worth $10,847,000 after purchasing an additional 581,856 shares during the period. Finally, Alps Advisors Inc. lifted its holdings in shares of Immatics by 46.2% during the 3rd quarter. Alps Advisors Inc. now owns 198,239 shares of the company's stock valued at $1,741,000 after purchasing an additional 62,640 shares in the last quarter. 64.41% of the stock is currently owned by institutional investors and hedge funds.

Immatics Company Profile

(Get Free Report)

Immatics is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer. Founded in Germany in 2000, the company uses its target-discovery and development platforms to identify cancer-associated targets and create therapies designed to direct the immune system against tumor cells. Its pipeline includes engineered T-cell receptor (TCR) T-cell therapies, which modify a patient's T cells to recognize specific tumor targets, as well as TCR bispecific therapies designed to connect T cells with cancer cells.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Immatics Right Now?

Before you consider Immatics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immatics wasn't on the list.

While Immatics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines